[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C][C][C][C][C][=Branch1][C][=O][O][C][C][Branch1][=N][C][O][C][=Branch1][C][=O][C][C][C][C][C][C][O][C][=Branch1][C][=O][C][C][C][C][C][C]"}, {"from": "gpt", "value": "The molecule is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.  Triheptanoin was granted FDA approval on 30 June 2020."}]